In clinical trials, an IFN-γ treatment improved the survival in patients with ovarian cancer of stage Ic-IIIc [208], upon intra-vesical administration to patients with transitional-cell bladder carcinoma [209] or used for isolated-limb perfusion of individuals with non-melanoma cancers of the extremities [210]. The gene discussed is IFNG; the disease is cancer.